Sun Pharma is not the only one which is facing increase in competition in the generics market along with greater pricing scrutiny in the US. Glenmark Pharmaceuticals also reported a 4.2 per cent year-on-year drop in September quarter consolidated net profit to Rs 214.12 crore on weak US sales, the ...
Read more: Pharma: Shrinking Fortunes